TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas

Cytopathology

Volumn 14, Issue 6, 2003, Pages 314-319

  Bofin, A M ^a,c   Ytterhus, B ^a   Hagmar, B M ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Breast cancer; Fine needle aspiration cytology; Fluorescence in situ hybridization; HER 2; TOP2A

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER THERAPY; CELL PROLIFERATION; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE LOCATION; GENE PROBE; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; SMEAR; TOP2A GENE;

ANTIGENS, NEOPLASM; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 0346125406     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0956-5507.2003.00088.x     Document Type: Article

References (26)

1. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
2. Villman K, Ståhl E, Liljegren G, Tidefelt U, Karlsson MG. Topoisomerase IIa expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 2002;15:486-91.
3. Rudolph P, Olsson H, Bonatz G et al. Correlation between p53, c-erbB-2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999;187:207-16.
4. Järvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase II-α associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
5. Jarvinen TAH, Liu ET. Effects of HER2/neu on chemosensitivity of tumor cells. Drug Resist Updat 2000;3:319-24.
6. Järvinen TAH, Tanner M, Bärlund M, Borg Å, Isola J. Characterization of Topoisomerase IIalpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-50.
7. Di Leo A, Gancberg D, Larismont D et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with anthracycline-based therapy, or with cyclophosphamide, methotrexate, and 2-fluorouracil. Clin Canc Res 2002;8:1107-16.
8. Plummer SJ, Paris MJ, Myles J et al. Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. Genes Chromosomes Cancer 1997;20:354-62.
9. Gunnarsson C, Ahnström M, Kirschner K et al. Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 2003;22:34-40.
10. Coon JS, Marcus E, Gupta-Bert S et al. Amplification and overexpression of topoisomerase II-α predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Canc Res 2002;8:1061-7.
11. Glöckner S, Buurman H, Kleeberger H, Lehmann U, Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-26.
12. Park K, Kim J, Lim S, Han S. Topoisomerase IIα and Her2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003;39:631-4.
13. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000; 13:37-45.
14. Wang S, Saboorian H, Frenkel EP et al. Aneusomy 17 in breast cancer: its role in Her-2/neu protein expression and implication for clinical assessment of Her-2/neu status. Mod Pathol 2002;15:137-45.
15. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991;19:403-10.
17. Dabbs DJ, Silverman JF. Prognostic factors from the fine-needle aspirate: breast carcinoma nuclear grade. Diagn Cytopathol 1994;10:203-8.
18. Briffod M, Le Doussal V, Spyratos F. Cytological nuclear grading of fine needle cytopunctures of breast carcinoma. Analyt Quant Cytol Histol 1997;19:114-22.
19. Škrbínc A, Bábic T, Cúfer T, Us-Krášovec M. Cytological grading of breast cancer in Giemsa-stained fine needle aspiration smears. Cytopathology 2001;12:15-25.
20. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
21. Bofin AM, Ytterhus B, Fjøsne HE, Hagmar BM. Abnormal chromosome 8 copy number in cytological smears from breast carcinomas detected by means of fluorescence in situ hybridization (FISH). Cytopathology 2003; 14:5-11.
22. Visscher DW, Wallis T, Ritchie CA. Detection of chromosome aneuploidy in breast lesions with fluorecence in situ hybridisation: comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis. Cytometry 1995;21:95-100.
23. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8:933-8.
24. Durbecq V, Di Leo A, Cardoso F et al. Comparison of topoisomerase IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003;77:199-204.
25. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;224:707-12.
26. Guérin E, Entz-Werlé N, Eyer D et al. Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Leukemia 2003;17:532-40.